Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;75(11):e14650.
doi: 10.1111/ijcp.14650. Epub 2021 Aug 10.

Recent therapeutic targets in diabetic nephropathy

Marwa Mohsen  1 , Ahmed A Elberry  2 , Alaa Mohamed Rabea  3 , Mohamed E A Abdelrahim  1 , Raghda R S Hussein  1
Affiliations
Review

Recent therapeutic targets in diabetic nephropathy

Marwa Mohsen et al. Int J Clin Pract. 2021 Nov.

Abstract

Background: The prevalence of diabetes mellitus has been increased dramatically which in turn leads to complications including cardiovascular diseases, diabetic kidney disease, and substantially end-stage renal disease.

Methods: We reviewed articles discussing the pathophysiology of diabetic nephropathy with new agents that may be useful in the management of the disease. We used PubMed, Scopus, Google Scholar and the Open-access searching engines.

Results: The recent recommendations primarily depend on glycaemic and blood pressure control and the use of standard renin-angiotensin system blockade. Currently, the use of agents with nephroprotective effects beyond the hyperglycaemic lowering effect has been evidenced clinically.

Conclusions: In his review, the pathophysiology, clinical manifestations, and lines of treatment of diabetic nephropathy are discussed. In addition, a focus on the clinical role and nephroprotective effects of the emerging therapeutic class, dipeptidyl peptidase IV (DPP-4) inhibitors, is addressed in detail.

Keywords: CKD; DPP-4 inhibitors; T2D; albuminuria; diabetic nephropathy.

PubMed Disclaimer

References

REFERENCES

    1. Satirapoj B. Tubulointerstitial biomarkers for diabetic nephropathy. J Diabetes Res. 2018;2018:1-6.
    1. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Investig. 2014;124(6):2333-2340.
    1. Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884-895.
    1. Toth-Manikowski S, Atta MG. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015:1-16.
    1. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Kor J Physiol Pharmacol. 2014;18(1):1-14.

MeSH terms

Substances

LinkOut - more resources